April 29, 2021 -- Bavarian Nordic reported that additional preclinical data confirms its COVID-19 vaccine candidate can induce neutralizing antibodies against SARS-CoV-2 variants.
The company previously reported data that suggests two doses of its capsid viruslike particle (cVLP) COVID-19 vaccine candidate (ABNCoV2) led to more than fiftyfold higher titers of neutralizing antibodies against the wild-type (Wuhan) virus when compared to titers measured in convalescent human samples, and that this translated into protection from a challenge with wild-type virus.
Most recently, a neutralization test of samples from the study has confirmed similarly high levels of neutralizing antibodies against the SARS-CoV2 variants B.1.1.7 (British) and B.1.351 (South African), the company stated in a release.
Bavarian plans on starting a phase II trial in the second quarter of 2021 to look at the ability of ABNCoV2 to boost existing immunity through prior vaccination and create a more durable immune response that could protect against current circulating COVID-19 variants.
Copyright © 2021 scienceboard.net